OCUL
Ocular Therapeutix, Inc.Marquee-fund ownership over time
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Citadel Advisors | Q3 2024(8Q snapshot) | 7Q | $7.99 | $8.38 | +5% |
| Two Sigma Investments | Q3 2024(8Q snapshot) | 7Q | $7.99 | $8.38 | +5% |
| Point72 Asset Management | Q3 2024(8Q snapshot) | 7Q | $7.99 | $8.38 | +5% |
| AQR Capital Management | Q4 2024(8Q snapshot) | 6Q | $9.92 | $8.38 | -16% |
| D.E. Shaw | Q1 2025(8Q snapshot) | 5Q | $7.28 | $8.38 | +15% |
| Millennium Management re-entered | Q1 2025(8Q snapshot) | 5Q | $7.28 | $8.38 | +15% |
| Renaissance Technologies re-entered | Q2 2025(8Q snapshot) | 4Q | $6.93 | $8.38 | +21% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at OCULAR THERAPEUTIX, INC. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Jun 5, 2026 — the most recent Form 4 on file — not from today.
- Form 40001104659-26-070956Jun 5, 2026
- Form 40001104659-26-067485May 28, 2026
- Form 40001104659-26-067483May 28, 2026
- Form 40001104659-26-067481May 28, 2026
- Form 40001104659-26-067478May 28, 2026
- Form 40001104659-26-042694Apr 13, 2026
- Form 40001104659-26-019805Feb 25, 2026
- Form 40001104659-26-019804Feb 25, 2026
- Form 40001104659-26-019803Feb 25, 2026
- Form 40001104659-26-019802Feb 25, 2026
- Form 40001104659-26-019257Feb 24, 2026
- Form 40001104659-26-019256Feb 24, 2026
- Form 40001104659-26-016668Feb 17, 2026
- Form 40001104659-26-016667Feb 17, 2026
- Form 40001104659-26-016666Feb 17, 2026
Fundamentals
XBRL · Ocular Therapeutix, Inc.Annual figures sourced directly from Ocular Therapeutix, Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for OCULAR THERAPEUTIX, INC — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 10-QQuarterly reportMay 5, 2026
- 8-KFORM 8-KMay 5, 2026
- DEF 14AProxy statementApr 30, 2026
- 8-KFORM 8-KFeb 27, 2026
- 10-KAnnual reportFeb 5, 2026
- 8-KFORM 8-KFeb 5, 2026
- 8-KFORM 8-KJan 23, 2026
- 8-KFORM 8-KDec 18, 2025
- 8-KFORM 8-KDec 5, 2025
- 10-QQuarterly reportNov 4, 2025
- 8-KFORM 8-KNov 4, 2025
- 8-KFORM 8-KSep 30, 2025
- 8-KFORM 8-KSep 30, 2025
- 10-QQuarterly reportAug 5, 2025
- 8-KFORM 8-KAug 5, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Renaissance Technologies | Q1 2026 | open | $9.06 | $8.38 | -8% |
| Millennium Management | Q3 2025 | open | $13 | $8.38 | -34% |
| Renaissance Technologies | Q2 2025 | Q4 2025 | $6.93 | $11 | +61% |
| D.E. Shaw | Q1 2025 | open | $7.28 | $8.38 | +15% |
| Millennium Management | Q1 2025 | Q2 2025 | $7.28 | $7.17 | -2% |
| AQR Capital Management | Q4 2024 | open | $9.92 | $8.38 | -16% |
| Citadel Advisors | Q3 2024 | open | $7.99 | $8.38 | +5% |
| Two Sigma Investments | Q3 2024 | open | $7.99 | $8.38 | +5% |
| Point72 Asset Management | Q3 2024 | open | $7.99 | $8.38 | +5% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.